Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?

Simply Wall St.12-08

Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589858805?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-08 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589858805","market":"hk","top_or_hot":-1,"title":"Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 02:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRNX","symbol_name":"Crinetics Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr","article_id":"2589858805","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589858805","pubTimestamp":1765131099,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine and other SST2-expressing solid tumors.\nThe trial marks the first clinical test of Crinetics’ nonpeptide drug conjugate platform, which aims to deliver potent cytotoxic therapy selectively to SST2-expressing tumor cells using small-molecule manufacturing rather than antibody or...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRNX":"Crinetics Pharmaceuticals Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"CRN09682的首次人体BRAVESST2试验是否改变了Crinetics Pharmaceuticals(CRNX)的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRNX":1.5},"content_text":"Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine and other SST2-expressing solid tumors. The trial marks the first clinical test of Crinetics’ nonpeptide drug conjugate platform, which aims to deliver potent cytotoxic therapy selectively to SST2-expressing tumor cells using small-molecule manufacturing rather than antibody or radiopharmaceutical approaches. Next, we’ll examine how this first-in-human trial of CRN09682, built on Crinetics’ nonpeptide drug conjugate platform, shapes its investment narrative. We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.AdvertisementWhat Is Crinetics Pharmaceuticals' Investment Narrative?For someone considering Crinetics, the basic belief is that its endocrine-focused pipeline can eventually justify years of losses and limited current revenue. The recent first-patient dosing of CRN09682 adds an earlier-stage, higher-risk oncology angle on top of the core paltusotine story, but it is unlikely to shift the near-term catalysts that still hinge on PALSONIFY’s commercial ramp in acromegaly and key Phase 3 data in carcinoid syndrome. Instead, BRAVESST2 subtly reshapes the risk–reward profile: success could broaden the franchise into SST2-expressing tumors, while setbacks would reinforce dependence on a single commercial asset in the face of heavy annual net losses and ongoing cash burn. Given the share price is still well below consensus fair value, how investors weigh these trade-offs is crucial. However, one operational risk tied to that widening pipeline may surprise some investors.\n\nCrinetics Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesCRNX Community Fair Values as at Dec 2025 Three Simply Wall St Community fair value views span roughly US$8 to over US$115, underscoring just how far apart individual expectations sit. When you set that against Crinetics’ high cash burn and reliance on upcoming paltusotine milestones, it becomes clear why many participants want to compare multiple viewpoints before deciding what the stock’s future might look like.Explore 3 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be worth over 2x more than the current price!Build Your Own Crinetics Pharmaceuticals NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.Looking For Alternative Opportunities?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Uncover the next big thing with financially sound penny stocks that balance risk and reward.Outshine the giants: these 26 early-stage AI stocks could fund your retirement.Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589858805","isCrawlerRequest":true}